Announced Wed, 10 Jun · 15:58 IST

This is to inform you that Sudarshan Industries Inc. has been incorporated as a wholly-owned subsidiary in United States of America. Details provioded in the Letter and its Annexure.

Strategic Transactions View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.0%1-day move
₹35.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.0+6.9+8.6+8.3+5.5+8.3+13.7+20.0
Up moveDown movePending
AI summary

Sudarshan Pharma Industries has incorporated a wholly-owned subsidiary called Sudarshan Industries Inc. (Sudarshan USA) in Delaware, USA, on June 5, 2026. The company subscribed to 1,00,00,000 shares of US $0.00001 each, totaling roughly US $100 (~₹9,600), giving it 100% ownership. The subsidiary will handle buying, selling, manufacturing, importing, and exporting pharmaceuticals, APIs, drugs, chemicals, and healthcare products to grow the company's customer base in the US market. Joint Managing Director Sachin Mehta has been appointed as the first director, and the investment was made under the RBI's automatic route under FEMA.

Likely market impact

This is a small, initial step towards entering the US pharma market, with negligible immediate financial impact given the token capital outlay. Future capital infusion into this subsidiary will be the real indicator of how serious the US push is, so investors should watch for follow-up disclosures on actual business operations or further funding.